TABLE 2.
1 ME/CFS norm HRBP (n = 309) | 2 ME/CFS POTS (n = 226) | 3 HC norm BPHR (n = 34) | p‐value one‐way ANOVA with Tukey's post hoc test | |
---|---|---|---|---|
HR supine (bpm) | 73 (11) | 78 (12) | 70 (11) | F(2, 566) = 16.08, p < 0.0001; 1 vs. 2: p < 0.0001, 2 vs. 3: p = 0.0004 |
HR end‐tilt (bpm) | 88 (12) | 115 (17) | 84 (14) | F(2, 566) = 238.1, p < 0.0001; 1 vs. 2: p < 0.0001; 2 vs. 3: p < 0.0001 |
SBP supine (mmHg) | 136 (18) | 132 (16) | 133 (16) | F(2, 566) = 3.45, p = 0.03 |
SBP end‐tilt (mmHg) | 134 (19) | 126 (21) | 125 (14) | F(2, 566) = 11.74, p < 0.0001; 1 vs. 2: p < 0.0001 |
DBP supine (mmHg) | 81 (12) | 80 (10) | 78 (7) | F(2, 566) = 0.72, p = 0.49 |
DBP end‐tilt (mmHg) | 88 (14) | 87 (15) | 81 (9) | F(2, 566) = 3.84; p = 0.02 |
MAP supine (mmHg) | 103 (13) | 101 (12) | 97 (9) | F(2, 566) = 3.66, p = 0.03 |
MAP end‐tilt (mmHg) | 106 (15) | 104 (17) | 95 (10) | F(2, 566) = 7.84, p = 0.0004; 1 vs. 3: p = 0.0004 |
PETCO2 supine (mmHg) | 37 (3) | 36 (3) | 37 (3) | F(2, 566) = 3.53, p = 0.03 |
PETCO2 end‐tilt (mmHg) | 30 (5) | 26 (5) | 36 (3) | F(2, 566) = 61.80, p < 0.0001; 1 vs. 2: p < 0.0001; 1 vs. 3: p < 0.0001; 2 vs. 3: p < 0.0001 |
Delta CO2 end‐tilt min supine (mmHg) | −7 (4) | −10 (4) | −2 (1) | F(2, 566) = 65.44, p < 0.0001; 1 vs. 2: p < 0.0001; 1 vs. 3: p < 0.0001; 2 vs. 3: p < 0.0001 |
CBF supine (mL/min) | 610 (101) | 620 (98) | 621 (82) | F(2, 566) = 0.68, p = 0.51 |
CBF end‐tilt (mL/min) | 442 (84) | 429 (74) | 577 (79) | F(2, 566) = 51.01, p < 0.0001; 1 vs. 3: p < 0.0001; 2 vs. 3: p < 0.0001 |
%CBF end‐tilt—supine (mL/min) | −28 (7) | −31 (6) | −7 (2) | F(2, 566) = 197.4, p < 0.0001; 1 vs. 2: p < 0.0001; 1 vs. 3: p < 0.0001; 2 vs. 3: p < 0.0001 |
Abbreviations: CBF, cerebral blood flow; DBP, diastolic blood pressure; HC, healthy controls; HR, heart rate; MAP, mean arterial pressure; Norm HRBP, normal heart rate and blood pressure response during tilt test; PETCO2; end‐tidal carbon dioxide; POTS, postural orthostatic tachycardia syndrome during tilt test; SBP, systolic blood pressure.